Notable Price Action: Is Selling Emergent Biosolutions Inc Here a Winning Strategy?

Notable Price Action: Is Selling Emergent Biosolutions Inc Here a Winning Strategy?

The stock of Emergent Biosolutions Inc (NYSE:EBS) hit a new 52-week low and has $23.59 target or 5.00% below today’s $24.83 share price. The 7 months bearish chart indicates high risk for the $956.09 million company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $23.59 price target is reached, the company will be worth $47.80 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 93,581 shares traded hands. Emergent Biosolutions Inc (NYSE:EBS) has declined 30.42% since April 1, 2016 and is downtrending. It has underperformed by 31.64% the S&P500.

Emergent Biosolutions Inc (NYSE:EBS) Ratings Coverage

Out of 3 analysts covering Emergent Biosolutions (NYSE:EBS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Emergent Biosolutions has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Singular Research initiated the stock with “Buy” rating in Monday, March 28 report. The firm has “Outperform” rating by Wells Fargo given on Friday, February 19. On Monday, August 10 the stock rating was upgraded by Zacks to “Hold”. The rating was maintained by Singular Research with “Buy” on Tuesday, June 28. As per Friday, April 15, the company rating was initiated by Chardan Capital Markets.

According to Zacks Investment Research, “EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.”

Insitutional Activity: The institutional sentiment increased to 1.56 in 2016 Q2. Its up 0.33, from 1.23 in 2016Q1. The ratio improved, as 25 funds sold all Emergent Biosolutions Inc shares owned while 55 reduced positions. 35 funds bought stakes while 90 increased positions. They now own 35.17 million shares or 5.50% more from 33.34 million shares in 2016Q1.
Allianz Asset Mgmt Ag has 0% invested in the company for 93,487 shares. The New York-based Qs Ltd Liability Corp has invested 0.03% in Emergent Biosolutions Inc (NYSE:EBS). Putnam Investments Lc holds 0.01% or 201,490 shares in its portfolio. Credit Suisse Ag accumulated 51,484 shares or 0% of the stock. Teachers Retirement Systems Of The State Of Kentucky last reported 0% of its portfolio in the stock. Lsv Asset Management accumulated 0.02% or 302,035 shares. Advisory Limited Company holds 0% of its portfolio in Emergent Biosolutions Inc (NYSE:EBS) for 100 shares. State Of Tennessee Treasury Department last reported 24,170 shares in the company. Kistler has 9 shares for 0% of their US portfolio. Alps Advsr accumulated 68,308 shares or 0.02% of the stock. Blackrock Fund Advisors accumulated 2.01 million shares or 0.01% of the stock. Tci Wealth Advisors has 0% invested in the company for 58 shares. Camarda Fincl Ltd owns 70 shares or 0% of their US portfolio. California State Teachers Retirement Sys accumulated 0% or 68,111 shares. Kcg holds 33,792 shares or 0.02% of its portfolio.

Insider Transactions: Since May 12, 2016, the stock had 0 buys, and 10 sales for $10.67 million net activity. El-Hibri Fuad sold $1.71M worth of stock or 39,759 shares. Another trade for 4,700 shares valued at $207,364 was sold by JOULWAN GEORGE A. $380,494 worth of Emergent Biosolutions Inc (NYSE:EBS) shares were sold by Abdun-Nabi Daniel. Harsanyi Zsolt sold $1.18M worth of Emergent Biosolutions Inc (NYSE:EBS) on Tuesday, May 24. Another trade for 47,631 shares valued at $1.87 million was made by SULLIVAN LOUIS W on Thursday, May 12. Hauer Jerome M had sold 4,700 shares worth $180,950.

More notable recent Emergent Biosolutions Inc (NYSE:EBS) news were published by: Fool.com which released: “Why Emergent Biosolutions Inc Surged Higher Today” on September 30, 2016, also Fool.com with their article: “Why Emergent BioSolutions Inc. Procured a Lower Price Today” published on June 22, 2016, Forbes.com published: “Emergent BioSolutions Is Oversold” on June 27, 2016. More interesting news about Emergent Biosolutions Inc (NYSE:EBS) were released by: Fool.com and their article: “Emergent BioSolutions Inc. Asks for Patience” published on August 11, 2016 as well as Fool.com‘s news article titled: “Emergent BioSolutions Inc. Expanding Along” with publication date: March 07, 2016.

EBS Company Profile

Emergent BioSolutions Inc., incorporated on December 19, 2003, is a biopharmaceutical firm that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Firm develops, makes and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics, and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. The Company’s two operating divisions include Biodefense and Biosciences.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment